Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives

A Study to Evaluate the Potential Incidence of Orthostatic Hypotension in Elderly Hypertensive Patients Following Administration of a Combination of COREG CR and Lisinopril

This is a multi-center, double-blind, randomized, placebo-controlled, 2-session crossover study to evaluate the incidence of orthostatic hypotension in elderly hypertensive subjects following co-administration of carvedilol CR and lisinopril.

Study Overview

• Status: Completed
• Conditions: Hypertension
• Intervention / Treatment: Drug: Carvedilol CR capsules; Drug: Placebo; Drug: Lisinopril

• Study Type: Interventional
• Enrollment (Actual): 62
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Anniston, Alabama, United States, 36207
      • GSK Investigational Site
  • Arizona
    • Glendale, Arizona, United States, 85308
      • GSK Investigational Site
  • California
    • Anaheim, California, United States, 92801
      • GSK Investigational Site
    • Beverly Hills, California, United States, 90211
      • GSK Investigational Site
    • Long Beach, California, United States, 90806
      • GSK Investigational Site
  • Florida
    • Coral Gables, Florida, United States, 33134
      • GSK Investigational Site
    • Miami, Florida, United States, 33169
      • GSK Investigational Site
    • Sarasota, Florida, United States, 34239
      • GSK Investigational Site
    • West Palm Beach, Florida, United States, 33409
      • GSK Investigational Site
  • Idaho
    • Boise, Idaho, United States, 83704
      • GSK Investigational Site
  • Indiana
    • Indianapolis, Indiana, United States, 46260
      • GSK Investigational Site
  • Nevada
    • Las Vegas, Nevada, United States, 89119
      • GSK Investigational Site
  • New Jersey
    • Hackensack, New Jersey, United States, 07601
      • GSK Investigational Site
  • North Dakota
    • Fargo, North Dakota, United States, 58103
      • GSK Investigational Site
  • Ohio
    • Cleveland, Ohio, United States, 44122
      • GSK Investigational Site
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73132
      • GSK Investigational Site
  • Oregon
    • Portland, Oregon, United States, 97239
      • GSK Investigational Site
  • Texas
    • Austin, Texas, United States, 78704
      • GSK Investigational Site
    • Houston, Texas, United States, 77081
      • GSK Investigational Site
    • San Antonio, Texas, United States, 78229
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males or females who are ≥ 65 years of age
• Body mass index (BMI) between 24 and 37 kg/m2 where: BMI = (weight in kg)/ (height in meters)2
• Subjects must have a documented history of essential hypertension and must be stable on treatment with an ACE inhibitor or angiotensin II receptor antagonist or renin antagonist and no more than one other antihypertensive medication at least 3 months before screening with a sitting SBP<180 mmHg and DBP<110 mmHg.
• All subjects must be able to be safely (in the opinion of the Investigator) withdrawn or down-titrated from all antihypertensive treatment(s) and transitioned to lisinopril 10 mg OD for the two-week run-in phase.

Exclusion Criteria:

• Any clinically relevant abnormality identified on the screening history, physical or laboratory examination, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study
• Subject who metabolizes carvedilol poorly based on CYP2D6 genotype as determined at screening
• Subject has persistent hyperkalemia or history of hyperkalemia resulting from either Type IV RTA (renal tubular acidosis) or previous treatment with an ACE inhibitor, ARB or renin inhibitor.
• Subject has malignant (accelerated) hypertension, history of malignant hypertension, or history of secondary forms of hypertension
• Subject has advanced hypertensive retinopathy (Keith Wagner Grade IV)
• Subject has a history of hepatic impairment (characterized by prolonged prothrombin time/low concentrations of albumin) and/or renal insufficiency (subjects with an estimated CrCl ≤ 30 mL/min by Cockroft-Gault must be excluded). CrCL = [140-ageCr][weight/70] x 0.85 (if female); Cr in mg/dL; Weight in kg
• Subject is being treated for diabetes mellitus
• Subject has a history of angioedema
• Subject has been under treatment with 3 or more antihypertensive medications. (NOTE: A combination drug containing two antihypertensive agents represents two antihypertensive medications.)
• Subject has been under treatment with HCTZ > 12.5 mg/day

• Subject is receiving ongoing treatment or is anticipated to receive treatment with any of the following medications during the study:

  • monoamine oxidase inhibitors (MAO)
  • any Class I or III antiarrhythmic
  • alpha-adrenergic receptor blockers
  • beta-2-adrenergic agonists
  • all antidepressants including SSRIs
  • lithium
  • medications known to be inhibitors/inducers of cytochrome P-450 2D6 should be discontinued for at least 14 days or 5 half-lives [which ever is longer] prior to the first day of the run-in period
• Treatment with any over-the-counter medications , herbal and dietary supplements, as well as grapefruit-containing products within 7 days or 5 half-lives (whichever is longer) prior to first day of run-in period through the end of the study unless approved by the PI and GSK medical monitor. Standard vitamins and/or daily multi-vitamins are permitted, however herbal vitamins should be excluded.
• Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the run-in period
• Subject has mean sitting SBP ≥ 180 mmHg at the screening assessment (one set of repeat measurement is permitted as per approval by the medical monitor).
• Documented history of low blood pressure within six months of screening visit (average sitting SBP < 110 mm Hg and/or DBP /< 50 mm Hg) or blood pressure below these values at time of screening (one set of repeat measurement is permitted as per approval by the medical monitor).
• Orthostatic hypotension diagnosed at screening (orthostatic hypotension is defined as a reduction in systolic blood pressure of 20 mmHg or more and/or a reduction in diastolic blood pressure of 10 mmHg or more for standing vs. supine measurements)

• Subject has any of the following conditions:

  • uncontrollable or symptomatic arrhythmias; unstable angina
  • sick sinus syndrome or second or third degree heart block (unless treated with a permanent, functioning pacemaker)
  • bradycardia (seated heart rate <55 bpm) (one repeat measurement is permitted as per approval by the medical monitor) ; history of myocardial infarction, or history of stroke within 1 year of screening.
  • subject is in, or has a history of atrial fibrillation

• Any of the following abnormalities on 12-lead ECG during screening:

  • complete RBBB or LBBB
  • evidence of second- or third-degree AV block
  • pathological Q-waves (Q-wave wider than 0.04 sec or depth greater than 0.4-0.5 mV)
  • any other abnormalities that investigator feels could be of concern when patient is taking a β-adrenergic blocking agent
• Donation of blood in excess of 500 mL within a 56-day period including the estimated 150 mL of blood to be drawn during this study
• History of asthma, COPD and/or hypersensitivity to β -adrenergic blocking agents
• History of sensitivity to carvedilol, lisinopril, alpha-blockers, beta-blockers or ACE inhibitors
• History of sensitivity to any of the study medications or components thereof
• History of anaphylaxis or anaphylactoid reactions or severe allergic responses to drugs
• History of regular alcohol consumption exceeding 7 drinks/week for women or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening
• Unanticipated positive urine drug screen (UDS) at screening. Note: If the subject is taking a drug known to give a positive on the UDS, then this should be discussed with the medical monitor prior to sending the UDS. In this situation, with prior approval, a positive finding on the UDS will not be considered an exclusion
• Positive for Hepatitis B surface antigen or HIV
• Unwillingness or inability to follow the procedures outlined in the protocol or inability to provide written informed consent

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Subjects receiving treatment sequence AB; Eligible subjects will receive treatment sequence AB; A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).	Drug: Carvedilol CR capsules; The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.; Drug: Placebo; Placebo capsules to match each dose level will be provided.; Drug: Lisinopril; Lisinopril will be available as 10 milligrams tablets administered orally once daily.
Experimental: Subjects receiving treatment sequence BA; Eligible subjects will receive treatment sequence BA; B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).	Drug: Carvedilol CR capsules; The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.; Drug: Placebo; Placebo capsules to match each dose level will be provided.; Drug: Lisinopril; Lisinopril will be available as 10 milligrams tablets administered orally once daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Assessment of orthostasis 6 hours post dose on day 1, 7, 8, 14 in each dosing session	6 hours post dose on day 1, 7, 8, 14 in each dosing session
To evaluate the incidence of orthostatic hypotension (defined as a decrease in SBP of ≥20 mmHg and/or a decrease in DBP of ≥10 mmHg in changing from the supine to the standing position) following co-administration of COREG CR and lisinopril	Up to Day 14

Secondary Outcome Measures

Outcome Measure	Time Frame
Relationship of concentration of drug to events 6 hours post dose on day 1, 7, 8, 14 in each dosing session	6 hours post dose on day 1, 7, 8, 14 in each dosing session
Relationship of concentration of drug to events	6 hours post dose on day 1, 7, 8, 14 in each dosing session
To evaluate the safety and tolerability of the co-administration of COREG CR and lisinopril	Up to Day 24
To evaluate the relationship between the plasma concentrations of carvedilol and lisinopril and the occurrence of orthostatic hypotension following co-administration of COREG CR and lisinopril	6 hours post dose on day 1, 7, 8, 14 in each dosing session
To evaluate the effects of COREG CR on plasma renin activity	Up to Day 14

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• GSK has submitted manuscripts of these study results to peer-reviewed scientific journals which were not accepted for publication. GSK is providing the attached study results summary with a conclusion.

Helpful Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Study record dates

Study Major Dates

• Study Start (Actual): September 25, 2007
• Primary Completion (Actual): June 3, 2008
• Study Completion (Actual): June 3, 2008

Study Registration Dates

• First Submitted: July 26, 2007
• First Submitted That Met QC Criteria: July 26, 2007
• First Posted (Estimate): July 30, 2007

Study Record Updates

• Last Update Posted (Actual): August 9, 2017
• Last Update Submitted That Met QC Criteria: August 8, 2017
• Last Verified: August 1, 2017

More Information

Terms related to this study

• Keywords: hypertension; carvedilol; lisinopril
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Nervous System Diseases; Autonomic Nervous System Diseases; Primary Dysautonomias; Orthostatic Intolerance; Hypertension; Hypotension; Hypotension, Orthostatic; Physiological Effects of Drugs; Adrenergic beta-Antagonists; Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents; Vasodilator Agents; Enzyme Inhibitors; Protease Inhibitors; Protective Agents; Cardiotonic Agents; Membrane Transport Modulators; Calcium-Regulating Hormones and Agents; Calcium Channel Blockers; Antioxidants; Angiotensin-Converting Enzyme Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Carvedilol; Lisinopril
• Other Study ID Numbers: CFD109701

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Study Data/Documents

1. Statistical Analysis Plan
   Information identifier: CFD109701
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
2. Dataset Specification
   Information identifier: CFD109701
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
3. Informed Consent Form
   Information identifier: CFD109701
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
4. Study Protocol
   Information identifier: CFD109701
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
5. Clinical Study Report
   Information identifier: CFD109701
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
6. Individual Participant Data Set
   Information identifier: CFD109701
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
7. Annotated Case Report Form
   Information identifier: CFD109701
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register